Xianghong (Emily) Jing

Emily (Xianghong) Jing earned her Ph.D. from University of Illinois and completed post-doctoral studies at Northwestern University. She joined the US FDA’s office of Vaccine Research and Review (OVRR) in Center for Biologics Evaluation and Research (CBER) as a product quality reviewer in 2009 and moved to Office of Biotechnology products (OBP) in Center for Drug Evaluation and Research (CDER) in 2014. She is currently a product quality team leader in OBP for the review of Chemistry, Manufacturing and Control (CMC) sections for a variety of investigational New Drug Applications (INDs) and Biologics License Applications (BLAs), including BLAs for new biosimilars. She has participated prior approval inspections on biologic product manufacturing facilities domestically and internationally.